Spectral AI Inc. (NASDAQ:MDAI) revealed Monday the performance results of its DeepView System in connection with the completion of its Burn Validation Study. Spectral AI, which focuses on medical ...
DALLAS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...
DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from ...
DALLAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (Spectral AI or the Company), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable ...
Image source: The Motley Fool. Spectral AI (NASDAQ:MDAI) advanced its DeepView commercialization strategy with regulatory and financial milestones, including a timely FDA de novo submission and ...
Multispectral Imaging and Assessment of Burns Healing Potential: A Prospective Real-World Study to assess the DeepView Snapshot Imaging Platform – Sam Snelling, North Bristol NHS Trust, Bristol, ...
Spectral AI, Inc. (NASDAQ: MDAI) reported 2025 results on March 24 th after the market close. Highlights since the company’s third quarter release include the elevation of Vincent Capone to Chief ...
DALLAS, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...
Spectral Ai completed its De Novo application submission to the FDA for the DeepView System in June 2025, marking a major regulatory milestone. Revenue for the quarter declined 32.0% year over year to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results